

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

NCT06208137

Status	RECRUITING
Phase	Not Applicable
Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Enrollment	456 participants

Key Eligibility Criteria

Inclusion (3)

- Patients must be ≥ 16 years of age;
- Patients receiving haploidentical allo-HSCT;
- Patients have to sign an informed consent form before the start of the research procedure.

Exclusion (3)

- Tandem transplantation or multiple transplantations;
- Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
- Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.

Locations (1 total)

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China